XPO1 and primary cutaneous T-cell non-Hodgkin lymphoma: These results indicate the potential effectiveness of XPO1 inhibitors in CTCL treatment, highlighting the necessity for additional research to explore the in vivo impact of KPT-330 therapy in CTCL.